Community treatment orders (CTO’s) provide compulsory supervision outside of psychiatric hospital. They require patients to accept clinical monitoring in the community and enable them to be recalled to hospital for assessment if necessary. They do not authorise forcible treatment; however whilst on a CTO a patient may be ordered to meet certain requirements, such as [read the full story...]
Research suggests that many people with schizophrenia or related psychoses show a striking lack of insight into their condition (Dam, 2006). Poor insight can have a negative impact on several outcomes, including general adjustment (Stefanopoulou et al., 2009), quality of life (Drake et al., 2007), social functioning (Drake et al., 2007) and rehospitalisation. With this [read the full story...]
NICE Guidelines state that around three quarters of people with a diagnosis of schizophrenia experience a chronic illness: with recurrent episodes of remission and relapse. One way that chronic physical health conditions, such as diabetes and heart disease, are managed is by using early warning signs (EWS) training and this prevention strategy is now often [read the full story...]
People using antipsychotic drugs like chlorpromazine and haloperidol get [anticholinergic] side effects such as blurred vision, dry mouth and constipation but the proportion of people experiencing these is not clear. Past surveys are very old indeed, small and not really proper surveys at all. Their results had been perpetuated for decades without verification. They were [read the full story...]
Schizophrenia according to the NICE guidelines, is a relatively common illness and in the majority of cases takes a chronic course, requiring continued management and careful attention. In the treatment and management of schizophrenia, antipsychotic medications – like olanzapine, quetiapine or clozapine – are the first line intervention. Antipsychotics can be loosely divided into “first-generation” (“typical”) and [read the full story...]
What’s the relationship between violence and psychosis? It’s an emotive debate that’s been running for years. On the one hand we have the net curtain-twitching, tabloid-reading brigade who picture axe-wielding psychopaths as soon as they read the word schizophrenia. On the other we have patients, carers, mental health charities and many clinicians who claim that [read the full story...]
Recent work by Suzanne Fitzpatrick and colleagues from Heriot Watt University has investigated the experiences of people who are affected by what they call multiple exclusion homelessness; a combination of homelessness, substance misuse, ‘street’ activities such as begging and street drinking, and institutional care (e.g. prison). Their quantitative survey shows that there is considerable overlap [read the full story...]
Schizophrenia is a debilitating illness that affects an estimated 25 million people worldwide. People with the condition can experience a huge amount of disability (both social, physical and psychological), but we know that early intervention can help reduce the duration of the illness and prevent further episodes of relapse. People with schizophrenia usually experience a [read the full story...]
Everyone who read the extracts from Michael Schofield’s memoir, published by the Guardian on January 19th, must surely have been moved by the sometimes harrowing description of his daughter Janni who was diagnosed with child-onset schizophrenia aged just 7 years old. Janni is an exception, as schizophrenia generally starts between the ages of 15 and [read the full story...]
The NICE guideline on psychosis with coexisting substance misuse was published in 2011, which means it’s now nearly 3 years out of date. This is because guidelines take many months to produce, so by the time they are published the evidence in them is 1 year old at best. Some NICE guidelines are supplemented by [read the full story...]
